One Winthrop Square
14 articles with Scorpion Therapeutics
Scorpion Therapeutics, Inc. (“Scorpion Therapeutics”), a pioneering oncology company redefining the frontier of precision medicine through its Precision Oncology 2.0 strategy, today announced that Axel Hoos, M.D., Ph.D., Chief Executive Officer of Scorpion Therapeutics, will present a corporate overview at the Jefferies Healthcare Conference on Friday, June 10, 2022 at 9:30 a.m. ET in New York City.
Members include pioneers of cancer biology and computational biology who have discovered key drivers of the disease and advanced the discovery of new therapies.
Scorpion Therapeutics Presents Preclinical Proof-of-Concept Data Supporting the Development of Its Potentially Best-in-Class Mutant-Selective PI3Kα Inhibitor for the Treatment of Solid Tumors at the AACR Annual Meeting 2022
Scorpion Therapeutics, Inc. today announced preclinical proof-of-concept data for STX-478.
Scorpion Therapeutics, Inc. today announced the appointment of Saurabh Saha, M.D., Ph.D. to its Board of Directors.
Biopharma companies are preparing to unveil new data for various oncology programs at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans next month.
Scorpion Therapeutics, Inc. (“Scorpion Therapeutics”), a pioneering oncology company redefining the frontier of precision medicine through its Precision Oncology 2.0 strategy, today announced that it will share preclinical proof-of-concept data for STX-H1047-PI3Kα, its lead program targeting the H1047X-mutant form of phosphoinositide 3-kinase alpha (“PI3Kα”), in a late-breaking poster presentation at the American Association for Cancer Research (“AACR”) Annual Meeting 2022.
Scorpion Therapeutics Enters Agreement with AstraZeneca to Discover, Develop and Commercialize Novel Cancer Treatments Against ‘Undruggable’ Targets
Scorpion Therapeutics, Inc. today announced a collaboration with AstraZeneca (LSE/STO/NYSE: AZN) to discover, develop and commercialize precision medicines against previously hard-to-target cancer proteins, with the potential to transform oncology treatment.
The companies believe the collaboration, valued at more than $1.5 billion, for up to three small molecule therapeutics has the potential to transform oncology treatments.
BioSpace is proud to present its NextGen Bio “Class of 2022,” a list of up-and-coming life sciences companies in North America that recently launched.
Scorpion Therapeutics, Inc. has been selected by BioSpace to join its NextGen Bio “Class of 2022.” The recognition from BioSpace, a life sciences industry news outlet and career hub, highlights top up-and-coming biopharmaceutical companies to watch in the new year.
Scorpion Therapeutics Reveals Highly-selective Lead Programs Targeting Mutant PI3Kα and EGFR Exon 20, Two Established Cancer Drivers with Broad Therapeutic Applicability
Scorpion Therapeutics Reveals Highly-selective Lead Programs Targeting Mutant PI3K α and EGFR Exon 20, Two Established Cancer Drivers with Broad Therapeutic Applicability.
Scorpion Therapeutics announced its new CEO Dr. Axel Hoos while Tenax Therapeutics named Christopher Giordano as its new chief executive.
This week multiple companies have announced millions of investment dollars have flooded their coffers to advance research and development of multiple therapies. BioSpace is rounding up the announcements.
Industry veteran and experienced drug developer Gary D. Glick, Ph.D., named president and chief executive officer